免疫检查点抑制剂的肾脏并发症:综述
本综述讨论免疫检查点抑制的一般原理、毒性机制及治疗的肾脏并发症,并提出肾损伤发生时的诊断和治疗策略。目前已有六种药物获批临床使用,免疫治疗应答的恶性肿瘤范围从晚期黑色素瘤到霍奇金淋巴瘤、非小细胞肺癌、肾细胞癌等。检查点抑制虽带来临床获益,但免疫系统激活可导致显著的脱靶毒性风险。
要点
- 免疫检查点抑制剂已获批六种药物,可治疗黑色素瘤、霍奇金淋巴瘤、非小细胞肺癌、肾细胞癌等。
- 检查点抑制通过免疫系统激活可导致脱靶毒性,包括肾脏并发症。
- 综述提出肾损伤发生时的诊断和治疗策略。
核心结论
- 检查点抑制是癌症治疗的重要策略,可改善患者生存,但存在包括肾脏并发症在内的脱靶毒性风险。
- 综述提出了肾损伤发生时的诊断和治疗策略。
研究设计与样本
- 综述,讨论检查点抑制的一般原理、毒性机制、肾脏并发症及诊断治疗策略。
主要发现
- 已有六种药物获批临床使用,更多在研发管线中。
- 免疫治疗应答的恶性肿瘤包括晚期黑色素瘤、霍奇金淋巴瘤、非小细胞肺癌、肾细胞癌等。
- 检查点抑制可因免疫系统激活导致显著的脱靶毒性。
临床怎么用
- 临床使用检查点抑制剂时需关注肾脏并发症,发生肾损伤时按综述提出的诊断和治疗策略处理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunologic control of malignancy has long been recognized as an important determinant of disease progression. Recent advances in immunology have led to the focus on several mechanisms that can be targeted to achieve tumor suppression. In particular, checkpoint inhibition has evolved in less than a decade to become one of the most important strategies in cancer therapy, with a meaningful improvement in patient survival. Six agents have been approved for clinical use to date and many more are in the industry pipeline. The spectrum of malignancies responsive to immunotherapy ranges from advanced melanoma, for which the first immune checkpoint inhibitor ipilimumab was approved, to Hodgkin lymphoma, non-small cell lung cancer, renal cell carcinoma, and others. Notwithstanding its clinical benefits, checkpoint inhibition carries a risk for significant off-target toxicity stemming from the immune system activation. In this review, we discuss general principles of checkpoint inhibition, mechanisms of toxicity, and kidney complications of the treatment and propose diagnostic and treatment strategies when kidney injury occurs.
引用
- Shingarev R, Glezerman IG. Kidney Complications of Immune Checkpoint Inhibitors: A Review. Am J Kidney Dis. 2019. PMID: 31303350. doi:10.1053/j.ajkd.2019.03.433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。